Start free

Lyell Immunopharma, Inc. (LYEL) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 12, 2026.

Filings shown
33
Open-market buys
1
Open-market sells
20
Buys, 10b5-1 box not checked
1 of 1

Counts cover the 33 most recent Form 4 filings Tradune holds for LYEL (filed Jun 11 – Nov 12, 2026); the score below covers only the trailing 90 days (1 buy, 6 sells). SEC EDGAR Form 4 filings for LYEL last checked Nov 21, 2026, 09:00 UTC; the latest LYEL filing Tradune holds was filed Nov 12, 2026. This is not guaranteed to be the complete record — see LYEL's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 11 filings Tradune holds for LYEL filed Aug 25 – Nov 12, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

9 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
0 sales· 0 sh
checkbox disclosed
On filings with the box not checked
9 sales· 14,135 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Lynn SeelyPresident and CEO 0 2 — 10,134 −$157,695
Gary K. LeeChief Scientific Officer 0 2 — 1,586 −$24,697
Stephen J. HillChief Operating Officer 0 2 — 1,077 −$16,771
Arch Venture Fund Xiii, L.P.10% owner 1 0 2,321,262 — +$24,999,992
David ShookChief Medical Officer 0 1 — 500 −$6,350
Jarrad Mattieu AguirreChief Medical Officer 0 1 — 422 −$3,642
Veronica Sanchez BulisVP, Corporate Controller 0 1 — 416 −$6,627

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

39/ 100

Net insider purchases
1 distinct buyer1 buy · 6 sell tx

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

Weekly signal history

LYEL appeared in 1 archived weekly edition as a multi-insider cluster, a top net buyer, or both. These are frozen weekly snapshots, not a complete filing history.

  1. Week of Nov 10, 2026
    2 insiders buying · $49,999,983 net 2 open-market buys · $49,999,983 net

An entry means this company met that edition’s displayed cluster or top-buyer threshold. Missing weeks do not mean no insider transaction occurred. All figures are derived from SEC Form 4 filings; open-market buys minus sales are shown as net only when every transaction value was disclosed.

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at LYEL

Insiders reported 1 open-market purchase of LYEL between Jun 11, 2026 and Nov 12, 2026, across 1 distinct buyer. The most recent purchase was reported by Arch Venture Fund Xiii, L.P. (10% owner) on Nov 4, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Veronica Sanchez Bulis VP, Corporate Controller · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 416 $15.93 14,383 −2.8% Nov 10, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Gary K. Lee Chief Scientific Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 129 $15.93 16,091 −0.8% Nov 10, 2026
Stephen J. Hill Chief Operating Officer · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 88 $15.93 16,728 −0.5% Nov 10, 2026
Lynn Seely President and CEO · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 545 $15.93 63,354 −0.9% Nov 10, 2026
Arch Venture Fund Xiii, L.P. 10% owner · filed Nov 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 2,321,262 $10.77 3,747,790 (indirect) +163% Nov 4, 2026
Jarrad Mattieu Aguirre Chief Medical Officer · filed Oct 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 422 $8.63 19,857 −2.1% Oct 12, 2026
Jarrad Mattieu Aguirre Chief Medical Officer · filed Sep 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Option (right to buy) 47,500 — — — Sep 10, 2026
David Shook Chief Medical Officer · filed Sep 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 500 $12.70 20,423 −2.4% Sep 10, 2026
Gary K. Lee Chief Scientific Officer · filed Aug 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 1,457 $15.54 16,220 −8.2% Aug 21, 2026
Stephen J. Hill Chief Operating Officer · filed Aug 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 989 $15.54 16,816 −5.6% Aug 21, 2026
Lynn Seely President and CEO · filed Aug 25, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 9,589 $15.54 63,899 −13% Aug 21, 2026
Veronica Sanchez Bulis VP, Corporate Controller · filed Aug 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 621 $14.34 14,799 −4.0% Aug 10, 2026
Gary K. Lee Chief Scientific Officer · filed Aug 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 131 $14.34 17,677 −0.7% Aug 10, 2026
Stephen J. Hill Chief Operating Officer · filed Aug 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 89 $14.34 17,805 −0.5% Aug 10, 2026
Lynn Seely President and CEO · filed Aug 11, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 390 $14.34 73,488 −0.5% Aug 10, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Other acquisition / disposition 44,000 — 2,774,980 −1.6% Jul 27, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jul 27, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Other acquisition / disposition 38,500 — 2,818,980 −1.3% Jul 27, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jul 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 10 $13.70 2,857,480 −0.0% Jul 17, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jul 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box checked 10 $13.73 2,857,490 −0.0% Jul 16, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jul 1, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Other acquisition / disposition 76,000 — 2,857,500 −2.6% Jun 29, 2026
Innovative Cellular Therapeutics Holdings Ltd 10% owner · filed Jun 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Other acquisition / disposition 66,500 — 2,933,500 −2.2% Jun 15, 2026
Veronica Sanchez Bulis VP, Corporate Controller · filed Jun 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 217 $18.91 15,420 −1.4% May 11, 2026
Gary K. Lee Chief Scientific Officer · filed Jun 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 130 $18.92 17,808 −0.7% May 11, 2026
Stephen J. Hill Chief Operating Officer · filed Jun 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 89 $18.92 17,894 −0.5% May 11, 2026
Lynn Seely President and CEO · filed Jun 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market sale 10b5-1 box not checked 388 $18.91 73,878 −0.5% May 11, 2026

Listing the 25 most recent of 33 Form 4 filings held for LYEL; the 8 older filings (filed Jun 11 – Jun 12, 2026) are counted above but not listed here — see LYEL's full Form 4 filing history on SEC EDGAR.

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to LYEL's (Nov 12, 2026).

Frequently asked about LYEL insider activity

How many insiders bought LYEL stock in these Form 4 filings?

1 distinct insider at Lyell Immunopharma, Inc. reported 1 open-market purchase (Form 4 code P) of LYEL shares between Jun 11, 2026 and Nov 12, 2026, the most recent filed by Arch Venture Fund Xiii, L.P. (10% owner) on Nov 4, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for LYEL?

The most recent Form 4 on this page was filed by Lynn Seely (President and CEO) on Nov 12, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market LYEL insider purchase shown?

The largest open-market purchase among the filings shown was 2,321,262 LYEL shares at $10.77 (about $24,999,992) by Arch Venture Fund Xiii, L.P. (10% owner) on Nov 4, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent LYEL insider purchases have the Form 4 10b5-1 box checked?

No. The one LYEL open-market purchase shown was reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Arch Venture Fund Xiii, L.P. (10% owner) on Nov 4, 2026, 2,321,262 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for LYEL — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.